RGC
Regencell Bioscience Holdings Limited
1W: +17.8%
1M: -18.2%
3M: +62.8%
YTD: +33.2%
1Y: +3280.1%
3Y: +3614.5%
$27.37
+0.36 (+1.33%)
After Hours: $26.85 (-0.52, -1.90%)
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Watch
25
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$13.5B
52W Range0.55263-83.6
Volume106,625
Avg Volume461,801
Beta2.07
Dividend—
Analyst Ratings
Company Info
CEOYat-Gai Au
Employees12
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
IPO Date2021-07-16
Websiteregencellbioscience.com
First Commercial Building
Causeway Bay KY1-1107
HK
Causeway Bay KY1-1107
HK
852 2155 0823
About Regencell Bioscience Holdings Limited
Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.
Latest News
12 Health Care Stocks Moving In Wednesday's Intraday Session
Miles Christen Brooke, VP at RGC Resources, buys $100 in stock - Investing.com Nigeria
How RGC Corp (RGC) Affects Rotational Strategy Timing - Stock Traders Daily
RGCO - Rgc Resources Latest Stock News & Market Updates - Stock Titan
Regencell Bioscience (NASDAQ:RGC) Shares Gap Down - Time to Sell? - MarketBeat
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| ANSCHUTZ PHILIP F | D-Return | 12,440,000 | $23.00 | 2018-02-28 |
| ANSCHUTZ PHILIP F | D-Return | 23,708,639 | $23.00 | 2018-02-28 |
| CAMPBELL MICHAEL L | D-Return | 703,660 | $23.00 | 2018-02-28 |
| YEMENIDJIAN ALEX | D-Return | 21,880 | $23.00 | 2018-02-28 |
| TYRRELL JACK | D-Return | 136,684 | $23.00 | 2018-02-28 |